AKT1 and metabolic dysfunction-associated steatotic liver disease: This double‐blinded placebo‐controlled randomized clinical trial on obese patients with NAFLD showed that myo‐inositol (MI) supplementation (4 g/day) for 8 weeks resulted in significant increases in the fold changes of AMPK, AKT, and PDK‐1 genes in peripheral blood mononuclear cells.